Annexon (ANNX) to Release Earnings on Monday

Key Points

• Q1 2026 earnings due Monday, May 11 — Annexon will report results before the open with analysts forecasting EPS of ($0.30) and revenue of $5.5M; analysts expect about -$1 EPS for the current and next fiscal year and the company recently topped a quarter's estimate (reported ($0.28) vs. ($0.32) expected).
• Stock snapshot — ANNX traded around $5.64 (market cap ≈ $917M) with 50/200-day moving averages of $5.65/$5.03 and a 52-week range of $1.60–$7.18, reflecting recent volatility and relatively low trading volume versus its average.
• Insider, institutional and analyst activity — Insiders sold ~32,513 shares in the last three months (including an EVP sale) while a director bought 8,000 shares under a 10b5-1 plan; institutional buyers like Invesco materially increased positions, and the consensus rating is a Moderate Buy with a $17 price target.

Annexon (NASDAQ:ANNX - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Annexon to post earnings of ($0.30) per share and revenue of $5.50 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Annexon (NASDAQ:ANNX - Get Free Report) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.04. On average, analysts expect Annexon to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Annexon Price Performance

Shares of ANNX stock traded down $0.11 on Monday, reaching $5.64. 548,360 shares of the stock were exchanged, compared to its average volume of 2,556,955. The stock has a 50 day moving average price of $5.65 and a 200 day moving average price of $5.03. The stock has a market cap of $917.21 million, a PE ratio of -4.17 and a beta of 1.22. Annexon has a one year low of $1.60 and a one year high of $7.18.

Insider Activity at Annexon

In related news, EVP Ted Yednock sold 7,857 shares of the company's stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $5.11, for a total transaction of $40,149.27. Following the completion of the sale, the executive vice president directly owned 97,227 shares in the company, valued at $496,829.97. This represents a 7.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director William H. Carson acquired 8,000 shares of the company's stock in a transaction that occurred on Friday, April 10th. The stock was acquired at an average price of $6.20 per share, with a total value of $49,600.00. Following the acquisition, the director owned 70,405 shares in the company, valued at $436,511. The trade was a 12.82% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 32,513 shares of company stock worth $165,973 in the last three months. Insiders own 12.67% of the company's stock.

Institutional Trading of Annexon

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. grew its holdings in shares of Annexon by 381.5% during the fourth quarter. Invesco Ltd. now owns 972,449 shares of the company's stock valued at $4,882,000 after buying an additional 770,504 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in Annexon during the 4th quarter valued at about $52,000. XTX Topco Ltd increased its holdings in Annexon by 64.6% during the 4th quarter. XTX Topco Ltd now owns 243,313 shares of the company's stock worth $1,221,000 after purchasing an additional 95,473 shares in the last quarter. Ikarian Capital LLC bought a new position in shares of Annexon during the fourth quarter valued at about $1,156,000. Finally, Virtus Investment Advisers LLC increased its stake in Annexon by 27.5% in the 4th quarter. Virtus Investment Advisers LLC now owns 53,527 shares of the company's stock valued at $269,000 after buying an additional 11,540 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ANNX. Chardan Capital reiterated a "buy" rating and set a $16.00 price target on shares of Annexon in a research report on Friday, March 20th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Annexon in a research report on Monday, April 20th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Annexon in a research report on Wednesday, January 14th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Annexon currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.00.

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company's research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon's pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.